AR038024A1 - Un compuesto derivado de 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino[4,5-b] indol-1-carboxamida, procedimientos para su preparacion, composicion farmaceutica que lo comprende, medicamento que consiste en dicho compuesto, y compuestos intermediarios - Google Patents
Un compuesto derivado de 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino[4,5-b] indol-1-carboxamida, procedimientos para su preparacion, composicion farmaceutica que lo comprende, medicamento que consiste en dicho compuesto, y compuestos intermediariosInfo
- Publication number
- AR038024A1 AR038024A1 ARP020104928A ARP020104928A AR038024A1 AR 038024 A1 AR038024 A1 AR 038024A1 AR P020104928 A ARP020104928 A AR P020104928A AR P020104928 A ARP020104928 A AR P020104928A AR 038024 A1 AR038024 A1 AR 038024A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- preparation
- atom
- group
- carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto derivado de 3-heteroaril-3,5-dihidro-4-oxo-4H-piridazino[4,5-?]indol-1-carboxamida que responde a la fórmula general (1) que puede existir en estado de base, de sal de adición con ácidos, de solvato o de hidrato, en la cual X representa un átomo de H o halógeno; R1 representa un átomo de H o un grupo alquilo C1-4, R2 y R3 representan cada uno, independientemente del otro, un átomo de H o un grupo alquilo C1-4, o bien R2 y R3 forman, con el átomo de N que los lleva, un grupo pirrolidinilo, piperidinilo, morfolinilo, o 4-alquilpiperazinilo, y Het representa un grupo heteroaromático de tipo piridinilo, 1-oxidopiridinilo, quinolinilo, isoquinolinilo, pirimidinilo, pirazinilo, piridazinilo, el grupo heteroaromático puede llevar uno o varios átomos de halógeno y/o uno o varios grupos alquilo C1-4, alcoxilo C1-4. Procedimiento para su preparación, composición farmacéutica que lo comprende, medicamento que consiste en el compuesto de fórmula (1), e intermediarios de síntesis. El compuesto para la preparación de un medicamento destinado a la prevención o al tratamiento de las neuropatías periféricas, las afecciones de la motoneurona, la ansiedad, la epilepsia, los problemas del sueno, la insuficiencia renal aguda o crónica, la glomerulonefritis, la nefropatía diabética, la isquemia y la insuficiencia cardíaca, el infarto de miocardio, la isquemia de los miembros inferiores, el vasoespasmo coronario, la angina de pecho, las patologías asociadas a las válvulas cardíacas, las enfermedades cardíacas inflamatorias, los efectos secundarios debido a medicamentos cardiotóxicos o luego de una cirugía cardíaca, la ateroesclerosis y sus complicaciones tromboembólicas, la restenosis, los rechazos de injerto, las condiciones relacionadas con una proliferación o una migración incorrecta de las células musculares lisas, tumores y cánceres, los estrés cutáneos, las enfermedades inflamatorias crónicas, en especial la poliartritis reumatoide, y las enfermedades inflamatorias pulmonares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0116701A FR2833953B1 (fr) | 2001-12-21 | 2001-12-21 | DERIVES DE 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038024A1 true AR038024A1 (es) | 2004-12-22 |
Family
ID=8870861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104928A AR038024A1 (es) | 2001-12-21 | 2002-12-18 | Un compuesto derivado de 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino[4,5-b] indol-1-carboxamida, procedimientos para su preparacion, composicion farmaceutica que lo comprende, medicamento que consiste en dicho compuesto, y compuestos intermediarios |
Country Status (33)
Country | Link |
---|---|
US (4) | US7109194B2 (es) |
EP (1) | EP1458721B1 (es) |
JP (1) | JP5087204B2 (es) |
KR (1) | KR100936565B1 (es) |
CN (1) | CN100376579C (es) |
AR (1) | AR038024A1 (es) |
AT (1) | ATE346069T1 (es) |
AU (1) | AU2002361325B2 (es) |
BR (1) | BR0215174A (es) |
CA (1) | CA2465750C (es) |
CY (1) | CY1106029T1 (es) |
DE (1) | DE60216321T2 (es) |
DK (1) | DK1458721T3 (es) |
EA (1) | EA006251B1 (es) |
ES (1) | ES2276978T3 (es) |
FR (1) | FR2833953B1 (es) |
HK (1) | HK1065792A1 (es) |
HR (1) | HRP20040549B1 (es) |
HU (1) | HU229419B1 (es) |
IL (2) | IL161859A0 (es) |
IS (1) | IS2380B (es) |
ME (2) | ME00117B (es) |
MX (1) | MXPA04006144A (es) |
NO (1) | NO328587B1 (es) |
NZ (1) | NZ532996A (es) |
PL (1) | PL371201A1 (es) |
PT (1) | PT1458721E (es) |
RS (1) | RS51103B (es) |
SI (1) | SI1458721T1 (es) |
TW (1) | TWI275391B (es) |
UA (1) | UA77984C2 (es) |
WO (1) | WO2003055884A1 (es) |
ZA (1) | ZA200404245B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6278893B1 (en) | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
FR2838124B1 (fr) * | 2002-04-03 | 2004-05-28 | Sanofi Synthelabo | Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique |
US7732447B2 (en) * | 2006-06-22 | 2010-06-08 | Cephalon, Inc. | Fused [d]pyridazin-7-ones |
CN1995041B (zh) * | 2006-12-18 | 2012-06-27 | 沈阳药科大学 | 哒嗪并吲哚类衍生物及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2754262B1 (fr) * | 1996-10-08 | 1998-10-30 | Synthelabo | Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique |
FR2766823B1 (fr) * | 1997-07-30 | 1999-10-08 | Synthelabo | Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique |
FR2788776B1 (fr) * | 1999-01-26 | 2001-02-23 | Synthelabo | Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique |
FR2811990A1 (fr) * | 2000-07-24 | 2002-01-25 | Sanofi Synthelabo | DERIVES DE 1-(4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1 -CARBONYL)PIPERAZINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
-
2001
- 2001-12-21 FR FR0116701A patent/FR2833953B1/fr not_active Expired - Fee Related
-
2002
- 2002-11-20 EP EP02796852A patent/EP1458721B1/fr not_active Expired - Lifetime
- 2002-11-20 CA CA2465750A patent/CA2465750C/en not_active Expired - Fee Related
- 2002-11-20 WO PCT/FR2002/003979 patent/WO2003055884A1/fr active IP Right Grant
- 2002-11-20 SI SI200230482T patent/SI1458721T1/sl unknown
- 2002-11-20 PL PL02371201A patent/PL371201A1/xx unknown
- 2002-11-20 ES ES02796852T patent/ES2276978T3/es not_active Expired - Lifetime
- 2002-11-20 AT AT02796852T patent/ATE346069T1/de active
- 2002-11-20 AU AU2002361325A patent/AU2002361325B2/en not_active Ceased
- 2002-11-20 MX MXPA04006144A patent/MXPA04006144A/es active IP Right Grant
- 2002-11-20 ME MEP-2008-224A patent/ME00117B/me unknown
- 2002-11-20 RS YUP-503/04A patent/RS51103B/sr unknown
- 2002-11-20 JP JP2003556414A patent/JP5087204B2/ja not_active Expired - Fee Related
- 2002-11-20 CN CNB028253353A patent/CN100376579C/zh not_active Expired - Fee Related
- 2002-11-20 DE DE60216321T patent/DE60216321T2/de not_active Expired - Lifetime
- 2002-11-20 PT PT02796852T patent/PT1458721E/pt unknown
- 2002-11-20 DK DK02796852T patent/DK1458721T3/da active
- 2002-11-20 BR BR0215174-0A patent/BR0215174A/pt not_active IP Right Cessation
- 2002-11-20 ME MEP-224/08A patent/MEP22408A/xx unknown
- 2002-11-20 KR KR1020047009601A patent/KR100936565B1/ko not_active IP Right Cessation
- 2002-11-20 US US10/499,725 patent/US7109194B2/en not_active Expired - Lifetime
- 2002-11-20 EA EA200400560A patent/EA006251B1/ru not_active IP Right Cessation
- 2002-11-20 IL IL16185902A patent/IL161859A0/xx unknown
- 2002-11-20 UA UA20040503612A patent/UA77984C2/uk unknown
- 2002-11-20 NZ NZ532996A patent/NZ532996A/en not_active IP Right Cessation
- 2002-11-20 HU HU0402578A patent/HU229419B1/hu not_active IP Right Cessation
- 2002-12-18 TW TW091136504A patent/TWI275391B/zh not_active IP Right Cessation
- 2002-12-18 AR ARP020104928A patent/AR038024A1/es active IP Right Grant
-
2004
- 2004-05-06 IL IL161859A patent/IL161859A/en not_active IP Right Cessation
- 2004-05-10 IS IS7259A patent/IS2380B/is unknown
- 2004-05-31 ZA ZA2004/04245A patent/ZA200404245B/en unknown
- 2004-06-16 HR HRP20040549AA patent/HRP20040549B1/hr not_active IP Right Cessation
- 2004-06-17 NO NO20042536A patent/NO328587B1/no not_active IP Right Cessation
- 2004-11-01 HK HK04108556A patent/HK1065792A1/xx not_active IP Right Cessation
-
2006
- 2006-06-29 US US11/427,508 patent/US7402682B2/en not_active Expired - Fee Related
-
2007
- 2007-02-20 CY CY20071100220T patent/CY1106029T1/el unknown
-
2008
- 2008-06-17 US US12/140,608 patent/US7569567B2/en not_active Expired - Fee Related
-
2009
- 2009-06-19 US US12/487,902 patent/US20090275576A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190085008A1 (en) | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases | |
ES2288694T3 (es) | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. | |
JP2019031569A (ja) | Jak2およびalk2阻害剤およびその使用方法 | |
JP5827328B2 (ja) | リン酸輸送を阻害する化合物及び方法 | |
JP5825535B2 (ja) | Hec1活性の調節因子およびそのための方法 | |
CN108137639A (zh) | 烟酰胺单核苷酸衍生物及其用途 | |
JP2019514874A (ja) | Nad+を増大させる前駆体としてのニコチン酸リボシド又はニコチンアミドリボシド誘導体、及びその還元誘導体の使用 | |
CN103261198A (zh) | 2-芳基咪唑并[1, 2-b]哒嗪、2-苯基咪唑并[1, 2-a]吡啶、和2-苯基咪唑并[1, 2-a]吡嗪衍生物 | |
JP2013533886A (ja) | リン酸輸送を阻害する化合物及び方法 | |
JP2018509448A (ja) | 組合せ医薬 | |
ES2917526T3 (es) | Compuestos de aminonaptoquinona y composición farmacéutica para bloquear el sistema ubiquitinación-proteasoma en enfermedades | |
JP2012511021A (ja) | Rafの阻害剤およびその使用 | |
WO2016098005A1 (en) | Amido thiadiazole derivatives as nadph oxidase inhibitors | |
EP3019171B1 (en) | Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4) | |
CA3137985A1 (en) | Substituted pyrrolo [2, 3-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | |
JP4939220B2 (ja) | p38の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体 | |
US20100266674A1 (en) | L-oddc prodrugs for cancer | |
US20130196938A1 (en) | Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent | |
JPWO2007148835A1 (ja) | 抗ガン剤耐性克服剤 | |
ES2954148T3 (es) | Ciertos inhibidores de proteína cinasa | |
AR038024A1 (es) | Un compuesto derivado de 3-heteroaril-3,5-dihidro-4-oxo-4h-piridazino[4,5-b] indol-1-carboxamida, procedimientos para su preparacion, composicion farmaceutica que lo comprende, medicamento que consiste en dicho compuesto, y compuestos intermediarios | |
ES2711085T3 (es) | Hexahidrofuropirroles como inhibidores de PDE1 | |
BR112015030953B1 (pt) | Piridina fundidas de heterociclo de cinco membros, seus usos, e composição farmacêutica | |
ES2728932T3 (es) | Compuestos orgánicos | |
Krauze et al. | 3, 4-trans-4-Aryl-3-(1-pyridinio)-1, 2, 3, 4-tetrahydropyridine-6-thiolates—new group of potential cardiotonic drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FG | Grant, registration |